Shares of DexCom surged 10% to $82.00 in after-hours trading on July 30 after the glucose-monitor maker crushed second-quarter expectations and raised its full-year outlook, the latest signal that the company is shifting from a niche diabetes device maker into a broader metabolic-health platform. The question now: whether the stock, which sat below $72 just a week ago, has priced in the good news or still has room to run.
A Beat Across Every Line That Matters. DexCom posted Q2 revenue of $1.31 billion, up 13.1% year over year, beating analyst estimates of $1.29 billion. Adjusted earnings per share came in at $0.70, a 15.1% beat over the $0.61 consensus. Adjusted EBITDA hit $421.3 million, topping estimates by 7.8%.
Operating margin jumped to 24.3%, up from 18.4% a year ago — a 590-basis-point swing that means the company is keeping far more of each dollar it earns. For shareholders, profits are growing faster than revenue, a hallmark of a business gaining scale.
Raised Guidance Signals Confidence, Not Caution. The company slightly lifted its full-year revenue guidance to $5.22 billion at the midpoint, up from $5.21 billion. That figure sits within its initial 2026 outlook of $5.16 billion to $5.25 billion, or roughly 11% to 13% growth over 2025.
Management also raised its full-year operating margin outlook , reinforcing the profitability trend. While the revenue bump is modest, the margin upgrade matters more — it tells Wall Street that cost discipline is real, not just a one-quarter event.
The Type 2 Diabetes Pivot Could Redefine the Addressable Market. DexCom's over-the-counter glucose biosensor expanded the company's potential customer pool from 1.5 million core insulin users to over 37 million Americans with Type 2 diabetes who don't use insulin. Clinical data from the CONNECT randomized controlled trial showed its sensor delivers statistically significant blood-sugar improvements for Type 2 non-insulin patients.
Management expects commercial insurance coverage "for more than 7 million type 2 non-insulin lives by the end of this year." If adoption follows reimbursement, this is DexCom's biggest single revenue opportunity in years.
Valuation Isn't Demanding — Yet. At roughly 28 times forward earnings, DexCom trades above the 25-times average for U.S. medical-equipment companies , but below the premium multiples it commanded in 2023-2024. Intrinsic-value estimates run as high as $115 , suggesting upside — but only if the Type 2 expansion converts from clinical promise to recurring sensor revenue.